Drug Trial Radar · NCT07540416
Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
564
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Feb 29, 2028
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are: 1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch? 2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch. Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients. Participants will be randomly assigned (1:1) immediately after randomization: * Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg). * Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.
Conditions
- Acute Ischemic Stroke
Interventions
TNK-tPADrug
TNK-tPA (0.25 mg/kg, to maximum of 25mg)
AspirinDrug
Asprin (300mg)
PlaceboDrug
Asprin (placebo)
PlaceboDrug
TNK-tPA (placebo)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale (mRS)Time frame: 90 ± 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.